Besides a specific anti-melanoma effect, however, targeted agents may potentially restore the immune system activity and early studies proved that inhibition of BRAF cascade raises the number of CD8+ T-cells nearby tumor cells and increases the exposition of TAAs synthesized by melanoma cells. The gene discussed is CD8A; the disease is melanoma.